Company Information
- Type:
- Company
- Country:
- Brazil
- Sector:
- Pharmaceuticals & Biotechnology
- Ownership:
- Privately Held
- Global Compact Status:
- Active
- Participant Since
- 09 September 2015 Letter of Commitment
- Next Communication on Progress (COP) due on:
- 31 July 2025
Non-Financial Information
Communication On Progress
| Published On | Title | Level/Status |
|---|---|---|
| 29-Jul-2024 | 2024 Communication on Progress | Submitted |
| 29-Dec-2023 | 2023 Communication on Progress | Submitted |
| 01-Aug-2022 | Relatório Anual_2022_Eurofarma | Active |
| 11-Aug-2021 | Communication on Progress 2020/2021 | Active |
| 28-Aug-2020 | Comunicação de Progresso 2019/2020 | Active |
| 27-Aug-2019 | Comunicação de Progresso 2018/2019 | Active |
| 18-Oct-2018 | Relatório Anual 2018_ano base 2017 | Active |
| 18-Oct-2017 | Relatório_Eurofarma Laboratórios | Active |
| 24-Oct-2016 | Comunicação de Progresso_Eurofarma | Active |
| 10-Nov-2015 | relatorio-anual-2014-eurofarma-portuguese | Learner |
Note: Responsibility for the content of participants' public communication related to the Ten Principles of the UN Global Compact and their implementation lies with participants themselves and not with the UN Global Compact.
Note on levels: Not applicable refers to the period when the Communication on Progress (CoP) did not require differentiation levels. With the new CoP , for the 2022 Early Adopter Programme, and for 2023, there will be no differentiation levels.